TIGIT⁺ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.

ABSTRACT:

Background

Composition of the intestinal microbiota has been correlated to therapeutic efficacy of immune checkpoint inhibitors (ICI) in various cancer entities including melanoma. Prediction of the outcome of such therapy, however, is still unavailable. This prospective, non-interventional study was conducted in order to achieve an integrated assessment of the connection between a specific intestinal microbiota profile and antitumor immune response to immune checkpoint inhibitor therapy (anti-PD-1 and/or anti-CTLA-4) in melanoma patients.

Methods

We assessed blood and stool samples of 29 cutaneous melanoma patients who received immune checkpoint inhibitor therapy. For functional and phenotypical immune analysis, 12-color flow cytometry and FluoroSpot assays were conducted.

SUBMITTER: Tsakmaklis A 

PROVIDER: S-EPMC10685659 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature